InMode (NASDAQ:INMD) Price Target Cut to $26.00 by Analysts at Barclays

InMode (NASDAQ:INMD - Free Report) had its price target trimmed by Barclays from $27.00 to $26.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an overweight rating on the healthcare company's stock.

Other research analysts also recently issued reports about the company. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Thursday, October 31st. BTIG Research initiated coverage on shares of InMode in a report on Thursday, October 17th. They issued a "buy" rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $22.40.

InMode Stock Performance

Shares of InMode stock traded down $1.39 during trading hours on Thursday, hitting $16.01. The company's stock had a trading volume of 2,174,869 shares, compared to its average volume of 969,387. The company has a market cap of $1.34 billion, a PE ratio of 8.65 and a beta of 2.12. The business has a 50 day moving average price of $18.09 and a two-hundred day moving average price of $17.32. InMode has a 12-month low of $14.87 and a 12-month high of $26.80.

Institutional Trading of InMode

Several hedge funds have recently modified their holdings of INMD. Systematic Financial Management LP grew its holdings in shares of InMode by 13.3% in the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company's stock valued at $16,647,000 after purchasing an additional 115,492 shares in the last quarter. Barclays PLC lifted its position in InMode by 113.5% during the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock valued at $2,876,000 after purchasing an additional 90,173 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of InMode by 54.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company's stock worth $2,127,000 after buying an additional 44,058 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of InMode by 129.7% in the 2nd quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company's stock worth $1,659,000 after buying an additional 50,974 shares during the last quarter. Finally, State Street Corp raised its position in shares of InMode by 3.7% during the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock valued at $34,657,000 after buying an additional 73,183 shares in the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.